Short leukocyte telomere length (LTL) may be associated with several psychiatric disorders, including major depressive disorder (MDD). Short LTL has previously been associated with poor response to psychiatric medications in bipolar disorder and schizophrenia, but no studies have prospectively assessed the relationship of LTL to selective serotonin reuptake inhibitor (SSRI) response in MDD. We assessed pre-treatment LTL, depression severity [using the Hamilton Depression Rating Scale (HDRS)], and self-reported positive and negative affect in 27 healthy, unmedicated adults with MDD. The subjects then underwent open-label treatment with an SSRI antidepressant for 8 weeks, after which clinical ratings were repeated. The analyses were corrected for age, sex, and body mass index. ‘Non-responders' to treatment (HDRS improvement <50%) had significantly shorter pre-treatment LTL than ‘responders' (p = 0.037). Further, shorter pre-treatment LTL was associated with less improvement in negative affect (p < 0.010) but not with changes in positive affect (p = 0.356). This preliminary study is the first to assess the relationship between LTL and response to SSRIs in MDD and among the first to prospectively assess its relationship to treatment outcome in any psychiatric illness. Our data suggest that short LTL may serve as a vulnerability index of poorer response to SSRI treatment, but this needs examination in larger samples.

Keywords:
Telomere, Treatment response, Biomarker, Mood disorders, Selective serotonin reuptake inhibitors, Major depression, Antidepressants, Affect, Affective disorder, Depression
1.
Murray CJ, Vos T, Lozano R, et al: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-2223.
2.
Lindqvist D, Epel ES, Mellon SH, Penninx BW, Révész D, Verhoeven JE, Reus VI, Lin J, Mahan L, Hough CM, Rosser R, Bersani FS, Blackburn EH, Wolkowitz OM: Psychiatric disorders and leukocyte telomere length: underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev 2015;55:333-364.
3.
Verhoeven JE, Révész D, Wolkowitz OM, Penninx BW: Cellular aging in depression: permanent imprint or reversible process? An overview of the current evidence, mechanistic pathways, and targets for interventions. Bioessays 2014;36:968-978.
4.
Chan SR, Blackburn EH: Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 2004;359:109-121.
5.
Draskovic I, Londono Vallejo A: Telomere recombination and alternative telomere lengthening mechanisms. Front Biosci (Landmark Ed) 2013;18:1-20.
6.
Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, Nierenberg AA, Fava M, Wong KK: Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006;60:432-435.
7.
Verhoeven JE, Révész D, Epel ES, Lin J, Wolkowitz OM, Penninx BW: Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol Psychiatry 2014;19:895-901.
8.
Wikgren M, Maripuu M, Karlsson T, Nordfjäll K, Bergdahl J, Hultdin J, Del-Favero J, Roos G, Nilsson LG, Adolfsson R, Norrback KF: Short telomeres in depression and the general population are associated with a hypocortisolemic state. Biol Psychiatry 2012;71:294-300.
9.
Hartmann N, Boehner M, Groenen F, Kalb R: Telomere length of patients with major depression is shortened but independent from therapy and severity of the disease. Depress Anxiety 2010;27:1111-1116.
10.
Hoen PW, de Jonge P, Na BY, Farzaneh-Far R, Epel E, Lin J, Blackburn E, Whooley MA: Depression and leukocyte telomere length in patients with coronary heart disease: data from the Heart and Soul Study. Psychosom Med 2011;73:541-547.
11.
Lung FW, Chen NC, Shu BC: Genetic pathway of major depressive disorder in shortening telomeric length. Psychiatr Genet 2007;17:195-199.
12.
Schutte NS, Malouff JM: The association between depression and leukocyte telomere length: a meta-analysis. Depress Anxiety 2015;32:229-238.
13.
Cai N, Chang S, Li Y, et al: Molecular signatures of major depression. Curr Biol 2015;25:1146-1156.
14.
Simon NM, Walton ZE, Bui E, Prescott J, Hoge E, Keshaviah A, Schwarz N, Dryman T, Ojserkis RA, Kovachy B, Mischoulon D, Worthington J, DeVivo I, Fava M, Wong KK: Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. Psychoneuroendocrinology 2015;58:9-22.
15.
Schaakxs R, Verhoeven JE, Oude Voshaar RC, Comijs HC, Penninx BW: Leukocyte telomere length and late-life depression. Am J Geriatr Psychiatry 2015;23:423-432.
16.
Needham BL, Mezuk B, Bareis N, Lin J, Blackburn EH, Epel ES: Depression, anxiety and telomere length in young adults: evidence from the National Health and Nutrition Examination Survey. Mol Psychiatry 2015;20:520-528.
17.
Lin J, Blalock JA, Chen M, Ye Y, Gu J, Cohen L, Cinciripini PM, Wu X: Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. Cancer Epidemiol Biomarkers Prev 2015;24:336-343.
18.
Martinsson L, Wei Y, Xu D, Melas PA, Mathé AA, Schalling M, Lavebratt C, Backlund L: Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl Psychiatry 2013;3:e261.
19.
Yu WY, Chang HW, Lin CH, Cho CL: Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J Psychiatry Neurosci 2008;33:244-247.
20.
Li Z, Hu M, Zong X, He Y, Wang D, Dai L, Dong M, Zhou J, Cao H, Lv L, Chen X, Tang J: Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia. Sci Rep 2015;5:18553.
21.
Rasgon N, Lin KW, Lin J, Epel E, Blackburn E: Telomere length as a predictor of response to pioglitazone in patients with unremitted depression: a preliminary study. Transl Psychiatry 2016;6:e709.
22.
Wolkowitz OM, Mellon SH, Epel ES, Lin J, Dhabhar FS, Su Y, Reus VI, Rosser R, Burke HM, Kupferman E, Compagnone M, Nelson JC, Blackburn EH: Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress - preliminary findings. PLoS One 2011;6: e17837.
23.
Wolkowitz OM, Mellon SH, Epel ES, Lin J, Reus VI, Rosser R, Burke H, Compagnone M, Nelson JC, Dhabhar FS, Blackburn EH: Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol Psychiatry 2012;17:164-172.
24.
First MB: Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, American Psychiatric Press, 1997.
25.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
26.
Watson D, Clark LA, Tellegen A: Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:1063-1070.
27.
Cohen S, Williamson GM: Perceived stress in a probability sample of the United States; in Spacapan S, Oskamp S (eds): The Social Psychology of Health. Newbury Park, Sage, 1988.
28.
Dipietro L, Caspersen CJ, Ostfeld AM, Nadel ER: A survey for assessing physical activity among older adults. Med Sci Sports Exerc 1993;25:628-642.
29.
Post RM, Roy-Byrne PP, Uhde TW: Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry 1988;145:844-848.
30.
Lecrubier Y: How do you define remission? Acta Psychiatr Scand Suppl 2002;415:7-11.
31.
Cawthon RM: Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47.
32.
Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, Bigos M, Wolkowitz O, Mellon S, Blackburn E: Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. J Immunol Methods 2010;352:71-80.
33.
MacKinnon A, Jorm AF, Christensen H, Korten AE, Jacomb PA, Rodgers B: A short form of the Positive and Negative Affect Schedule: evaluation of factorial validity and invariance across demographic variables in a community sample. Pers Individ Diff 1999;27:405-416.
34.
O'Donovan A, Lin J, Tillie J, Dhabhar FS, Wolkowitz OM, Blackburn EH, Epel ES: Pessimism correlates with leukocyte telomere shortness and elevated interleukin-6 in post-menopausal women. Brain Behav Immun 2009;23:446-449.
35.
Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P: An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 2014;171:1278-1286.
36.
Eller T, Vasar V, Shlik J, Maron E: Pro- inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:445-450.
37.
Chang HH, Lee IH, Gean PW, Lee SY, Chi MH, Yang YK, Lu RB, Chen PS: Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun 2012;26:90-95.
38.
Kiecolt-Glaser JK, Gouin JP, Weng NP, Malarkey WB, Beversdorf DQ, Glaser R: Childhood adversity heightens the impact of later-life caregiving stress on telomere length and inflammation. Psychosom Med 2011;73:16-22.
39.
Révész D, Verhoeven JE, Milaneschi Y, de Geus EJ, Wolkowitz OM, Penninx BW: Dysregulated physiological stress systems and accelerated cellular aging. Neurobiol Aging 2014;35:1422-1430.
40.
Behr GA, Moreira JC, Frey BN: Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev 2012;2012:609421.
41.
Klengel T, Binder EB: Gene × environment interactions in the prediction of response to antidepressant treatment. Int J Neuropsychopharmacol 2013;16:701-711.
42.
Shalev I, Entringer S, Wadhwa PD, Wolkowitz OM, Puterman E, Lin J, Epel ES: Stress and telomere biology: a lifespan perspective. Psychoneuroendocrinology 2013;38:1835-1842.
43.
Effros RB: Kleemeier Award Lecture 2008 - the canary in the coal mine: telomeres and human healthspan. J Gerontol A Biol Sci Med Sci 2009;64:511-515.
44.
O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326-331.
45.
Bersani FS, Lindqvist D, Mellon SH, Penninx BW, Verhoeven JE, Révész D, Reus VI, Wolkowitz OM: Telomerase activation as a possible mechanism of action of psychopharmacological interventions. Drug Discov Today 2015;20:1305-1309.
46.
Preskorn S: Outpatient Management of Depression, ed 3. Caddo, Professional Communications, 2009.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.